QScreen AI Reports Internal Validation Results for Correctional Intake Platform: 100% Sensitivity on Suicide Risk and Withdrawal Detection Across 65 Calibrated Clinical Scenarios

Nine instruments validated against published standards including Columbia C-SSRS, CIWA-Ar, and COWS; paper-only workflow showed materially lower detection rates across the same scenarios; 60-day live pilot structured and ready Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening today reports internal validation results for its correctional intake platform across 65 calibrated clinical scenarios tested against published instrument thresholds. By digitizing the high-liability blind spots of correctional intake, QAI transforms a universal institutional risk into a scalable SaaS revenue model with zero-hardware deployment friction.